Connection
Jeffrey Bennett to Natalizumab
This is a "connection" page, showing publications Jeffrey Bennett has written about Natalizumab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.877 |
|
|
|
-
Kowarik MC, Astling D, Lepennetier G, Ritchie A, Hemmer B, Owens GP, Bennett JL. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. Neurotherapeutics. 2021 01; 18(1):364-377.
Score: 0.721
-
St?ve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 2007; 13(1):79-95.
Score: 0.069
-
Bennett JL. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurol Res. 2006 Apr; 28(3):291-8.
Score: 0.065
-
Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, St?ve O. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol. 2010 Aug; 67(8):923-30.
Score: 0.022